Evidence map›Paper›PMID 34582627›Full record

ArticleLiver international : official journal of the International Association for the Study of the Liver2022

Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation.

Andrea Marcellusi, Francesco Saverio Mennini, Murad Ruf, Claudio Galli, Alessio Aghemo, Maurizia R Brunetto, Sergio Babudieri, Antonio Craxi, Massimo Andreoni, Loreta A Kondili

Open access · hybridAbstract read
In one paragraph

Article in Liver international : official journal of the International Association for the Study of the Liver, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation.Liver international : official journal of the International Association for the Study of the Liver · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 2 countries.

Andrea MarcellusiEconomic Evaluation and HTA (EEHTA), CEIS, Faculty of Economics, University of Rome "Tor Vergata", Rome, Italy.ORCID 0000-0002-3974-3798
Francesco Saverio MenniniEconomic Evaluation and HTA (EEHTA), CEIS, Faculty of Economics, University of Rome "Tor Vergata", Rome, Italy.ORCID 0000-0002-4738-5505
Murad RufPublic Health, Medical Affairs, Gilead Science, London, UK.
Claudio GalliGlobal Medical and Scientific Affairs, Core Laboratory, Abbott, Rome, Italy.ORCID 0000-0002-0804-0387
Alessio AghemoDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.ORCID 0000-0003-0941-3226
Maurizia R BrunettoInternal Medicine, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.ORCID 0000-0001-8364-9152
Sergio BabudieriInfectious and Tropical Disease Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.ORCID 0000-0001-7291-8687
Antonio CraxiGastroenterology and Hepatology Unit, Department of Internal Medicine and Medical Specialties "PROMISE", University of Palermo, Palermo, Italy.ORCID 0000-0002-4480-9544
Massimo AndreoniDepartment of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.ORCID 0000-0002-3205-9758
Loreta A KondiliCenter for Global Health, Istituto Superiore di Sanità, Rome, Italy.ORCID 0000-0003-2656-224X
University of Rome Tor Vergata · ITGilead Sciences (United Kingdom) · GBHumanitas University · ITIstituto Superiore di Sanità · ITUniversity of Palermo · ITUniversity of Pisa · ITUniversity of Sassari · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesOptimized diagnostic algorithms to detect active infections are crucial to achieving HCV elimination. We evaluated the cost effectiveness and sustainability of different algorithms for HCV active infection diagnosis, in a context of a high endemic country for HCV infection.

methodsA Markov disease progression model, simulating six diagnostic algorithms in the birth cohort 1969-1989 over a 10-year horizon from a healthcare perspective was used. Conventionally diagnosis of active HCV infection is through detection of antibodies (HCV-Ab) detection followed by HCV-RNA or HCV core antigen (HCV-Ag) confirmatory testing either on a second sample or by same sample reflex testing. The undiagnosed and unconfirmed rates were evaluated by assays false negative estimates and each algorithm patients' drop-off. Age, liver disease stages distribution, liver disease stage costs, treatment effectiveness and costs were used to evaluate the quality-adjusted life-years (QALYs) and the incremental cost-effectiveness ratios (ICER).

resultsThe reference option was Rapid HCV-Ab followed by second sample HCV-Ag testing which produced the lowest QALYs (866,835 QALYs). The highest gains in health (QALYs=974,458) was obtained by HCV-RNA reflex testing which produced a high cost-effective ICER (€891/QALY). Reflex testing (same sample-single visit) vs two patients' visits algorithms, yielded the highest QALYs and high cost-effective ICERs (€566 and €635/QALY for HCV-Ag and HCV-RNA, respectively), confirmed in 99.9% of the 5,000 probabilistic simulations.

conclusionsOur data confirm, by a cost effectiveness point of view, the EASL and WHO clinical practice guidelines recommending HCV reflex testing as most cost effective diagnostic option vs other diagnostic pathways.

Indexed as

Hepatitis CHepatitis C, ChronicAlgorithmsAntiviral AgentsCost-Benefit AnalysisHepacivirusHumansAntiviral Agentscost-effectivenessHCV chronic infectionscreeningWHO targets

Identifiers

PMID34582627
PMCPMC9292516
OpenAlexW3203807963

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.